Clinical Trial Update: A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 study investigating RC48-ADC in combination with Triplizumab for myometrial invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)
• Triplizumab (triplizumab)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Bladder Cancer | Phase 2 | Status: UNKNOWN